Skip to content
10-Q

Quarterly Report

Hepion Pharmaceuticals, Inc. CTRVP HEPA

0001641172-25-011534

← back to feed
Filed
May 19, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 15, 2025 10.98M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $935.92K
Current Liabilities Q1 2025 · Dec 31, 2024 $3.14M
Total Liabilities Q1 2025 · Mar 31, 2025 $2.42M
Total Liabilities Q1 2025 · Dec 31, 2024 $3.48M
Current Assets Q1 2025 · Mar 31, 2025 $6.32M
Current Assets Q1 2025 · Dec 31, 2024 $1.61M
Total Assets Q1 2025 · Mar 31, 2025 $6.32M
Total Assets Q1 2025 · Dec 31, 2024 $1.61M
Shares Diluted restated Q1 2025 · Mar 31, 2024 101.45K sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.62M
Stockholders Equity Q1 2025 · Mar 31, 2024 $7.52M
Stockholders Equity Q1 2025 · Dec 31, 2023 $7.28M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$28.13
Eps Basic restated Q1 2025 · Mar 31, 2024 −$28.13
Sga Expense Q1 2025 · Mar 31, 2024 $2.64M
Rd Expense Q1 2025 · Mar 31, 2024 $2.54M
Net Income Q1 2025 · Mar 31, 2024 −$2.85M
Operating Income Q1 2025 · Mar 31, 2024 −$5.18M